Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study

Fig. 3

Landmark analysis, cumulative incidence of relapse, non-relapse mortality, leukemia-free survival (LFS) and overall survival (OS) among the non-transplant group, MRD+ group and MRD- group. The cut-off value was set at the median time from CAR-T cell infusion to haplo-HSCT (2.23 months). No HSCT: non-transplant group, MRD+: MRD+ group, MRD-: MRD- group

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us